Last reviewed · How we verify
BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg (bnt162b2-monovalent-omi-xbb-1-5-30-mcg)
BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg (generic name: bnt162b2-monovalent-omi-xbb-1-5-30-mcg) is a RNA therapeutics drug developed by Pfizer Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | bnt162b2-monovalent-omi-xbb-1-5-30-mcg |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | RNA therapeutics |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- COVID-19
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg CI brief — competitive landscape report
- BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg
What is BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg?
BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg (bnt162b2-monovalent-omi-xbb-1-5-30-mcg) is a RNA therapeutics drug developed by Pfizer Inc..
Who makes BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg?
BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg?
bnt162b2-monovalent-omi-xbb-1-5-30-mcg is the generic (nonproprietary) name of BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg.
What development phase is BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg in?
BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg is in Phase 1.
What are the side effects of BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg?
Common side effects of BNT162b2 Monovalent (OMI XBB.1.5) 30 mcg include Headache, COVID-19.